News | April 29, 2025
Pfizer Q1 2025 revenue drops 8% to $13.7 billion
Delivers robust earnings performance, successfully navigating a dynamic environment
Delivers robust earnings performance, successfully navigating a dynamic environment
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Raichur site is the group’s largest API facility and part of a wider network of seven sites
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Subscribe To Our Newsletter & Stay Updated
